Jump to Main Content

FDA Alerts

FDA Grants Accelerated Approval to Copanlisib for Relapsed Follicular Lymphoma

The U.S. Food and Drug Administration granted accelerated approval to copanlisib (ALIQOPA™, Bayer HealthCare Pharmaceuticals Inc.) for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies.